id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-305286-nbbg511n	Xu, Zihui	The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID‐19	2020-07-08		.txt	text/plain	4014	253	54	In this observational study, we characterized risk factors for severe COVID-19 with and without T2DM, and described the effects of commonly prescribed anti-hyperglycaemic drugs, and glucocorticoid therapy on clinical outcomes in hospitalized T2DM patients with severe COVID-19, which still remain unanswered. Information recorded included demographic data, medical history, underlying comorbidities, symptoms, signs, laboratory findings (e.g., random blood glucose on admission, cellular immunity, metabolic enzymes and other biochemical parameters), treatment measures (e.g., oxygen therapy, ventilator use), and drugs (e.g., insulin, anti-hyperglycaemic agents and glucocorticoids use). All of these indicate that diabetes status is a major risk factor for worse clinical outcomes/fatality in COVID-19 patients. 36 Our study found that a higher risk of all-cause fatality with GC treatment in severe COVID-19 patients with T2DM. GC treatment and fasting plasma glucose ≥11.1 mmol/L were found to be risk factors for fatality in diabetes patients with COVID-19. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China	./cache/cord-305286-nbbg511n.txt	./txt/cord-305286-nbbg511n.txt